Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by TH1902on Jul 27, 2022 3:09pm
246 Views
Post# 34854640

Will TH1902 extend life? Key question

Will TH1902 extend life? Key questionI'm no cancer doc, just trying to learn, seems to me that one patient on TH1902 had a 33 wk course with no worsening...or am I wrong on this???

Below is what Trodelvy has done:

Seems to me, TH1902 has potential but we NEED MORE DATA imo...

Source : https://www.google.com/search?q=trodelvy+life+extension+cancer&rlz=1C1CHBF_enCA879CA879&oq=trodelvy+life+extension+cancer&aqs=chrome..69i57j33i160l4.9672j0j15&sourceid=chrome&ie=UTF-8

The researchers found that people taking Trodelvy had an average progression-free survival time—a period without worsening of disease—of 4.6 months compared with 2.3 months for those on chemotherapy. The median overall survival time was 12.4 months versus 6.7 months, respectively.
Oct 21, 2021
<< Previous
Bullboard Posts
Next >>